Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Major Inclusion Criteria:~1. Participants diagnosed with ulcerative colitis.~2. Participants with moderate ulcerative colitis who satisfy all of the following criteria at Day of enrollment.~   1. Mayo Clinic scores of 6-10 .~  2. Endoscopic subscore greater than or equal to (\>=) 2.~  3. Rectal bleeding subscore \>=1.~3. Participants with inadequate response or intolerant to oral 5-ASA~4. Participants who are capable of providing written informed consent~Major Exclusion Criteria:~1. Participants with extensive detachment of mucosa or deep ulcer.~2. Participants with oral corticosteroid dependency.~3. Participants with a complication of marked reduction of immune function.~4. Participants who were clinically suspected to have a complication of infectious enteritis.~5. Participants with a history or complication of serious infection within 1 year prior to the day of enrollment.~6. Participants with central nervous system (CNS) neurological symptoms.~7. Participants with the following criteria:~   * Serious heart disease~  * Renal impairment~  * Hepatic impairment~8. Participants with a history of serious drug induced allergy with unknown cause.~9. Participants with malignant tumor or those whose treatments were completed in less than 5 years.~10. Participants with apparent psychological signs.~11. Pregnant women, nursing women, women with suspected pregnancy, women who wish to become pregnant during the period from informed consent through to the end of observation/examination at Week 8, and women who do not consent to the use of appropriate birth control methods.~12. Participants who are definitely eligible for surgical intervention such as large bowel perforation, major bleeding, and toxic megacolon syndrome, etc.~13. Participants who are participants of another clinical study including follow-up observation at the time of informed consent.~14. Participants who received another investigational drug within 12 weeks prior to the examinations/observation defined by the protocol.~15. Participants who received investigational drugs in the study of AJM300.~16. Participants determined to be ineligible for participation in this study by the investigator or sub-investigator.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- AJM300 960mg/dose (Type: EXPERIMENTAL): Participants will orally receive AJM300 960 mg tablets, three times daily after meals for 8 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will orally receive AJM300 placebo-matching tablets, three times daily after meals for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).